Last reviewed · How we verify
Nivolumab and Relatlimab
At a glance
| Generic name | Nivolumab and Relatlimab |
|---|---|
| Also known as | Opdualag |
| Sponsor | University of Wisconsin, Madison |
| Drug class | Programmed Death Receptor-1 Blocking Antibody [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
- Musculoskeletal pain
- Fatigue
- Rash
- Pruritus
- Diarrhea
- Decreased hemoglobin
- Decreased lymphocytes
- Increased AST
- Increased ALT
- Decreased sodium
- Headache
- Hypothyroidism
Serious adverse events
- Serious adverse reactions (overall)
- Adrenal insufficiency
- Anemia
- Colitis
- Pneumonia
- Acute myocardial infarction
- Back pain
- Myocarditis
- Pneumonitis
- Fatal adverse reactions
Key clinical trials
- Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer (PHASE2)
- Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma (PHASE2)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (PHASE2)
- A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) (PHASE2)
- Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis (PHASE1, PHASE2)
- Pan Tumor Rollover Study (PHASE2)
- Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study (PHASE2, PHASE3)
- Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nivolumab and Relatlimab CI brief — competitive landscape report
- Nivolumab and Relatlimab updates RSS · CI watch RSS
- University of Wisconsin, Madison portfolio CI